EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

biote Corp (BTMD) fair value: what the stock is really worth

As of Oct 5, 2026: fair value of biote Corp $1.03, price $1.12, upside -8.5%, quality 76 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US0906831039

BC biote Corp logo Some data Oct 5, 2026

biote Corp

BTMD · US

Quality WatchlistA strong company, but the current price is close to Fair Value.

Quality 76/100
Generates free cash flow
Ranks above peers (7/11)
Fair value $1.03 · Fairly valued (−8.5%)
Mixed Growth (revenue 5y +10.5 %/yr in USD)
Thin margins · 3.2% net margin (TTM)
Negative equity (buybacks among others)
Some data
Narrow moat 41/100
Watch biote Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.06 $1.12 Fair Value $1.03 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 5, 2026.

How to read this chart

60‑month range $1.12 – $10.06 · fair‑value band $0.6333 – $1.39 · the $1.12 price screens above the $1.03 fair value. Dashed = 300-day average. As of Oct 5, 2026.

Follow biote in your weekly email

Every Wednesday you see whether biote is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.

Show more

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

Stock analysis

biote Corp (BTMD) currently trades at $1.12, while our model-based Fair Value estimate is $1.03, so the stock looks roughly fairly valued today (gap 9.3%).

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $9.90 per share, and 21 of the 23 models we run sit above the $1.12 price.

Bear case: the Dividend Discount group reads lowest at $0.8900, and 2 of the 23 models stay below the price. Evidence for this calculation is medium.

Scenario range: $0.6333 (bear) to $1.39 (bull), the price of $1.12 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

biote Corp reported revenue of $192M in FY2025 versus $139M in FY2021, a compound +8.4%/yr. Reported net income was $27.0M in FY2025, compounding −4.6%/yr from FY2021.

Key figures

Market cap $39.0M · P/E ratio 8.2 · P/S ratio 1.16 · EPS (TTM) $0.1400 · Dividend yield 4.4% · Net margin 14.1% · Return on assets (EBIT) 18.0% · Operating margin 5.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −8%, BTMD screens richer than that median.

Fair Value models

Bear $0.6333 Fair Value $1.03 Bull $1.39
Price $1.12 · Upside -8.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1070 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $12.73 $21.29 $34.06 79
Growth DCF $12.89 $20.33 $30.69 78
Owner Earnings $11.01 $18.62 $29.97 75
All 23 models by family
DCF Models
FCF DCF $12.73 $21.29 $34.06 79
Owner Earnings $11.01 $18.62 $29.97 75
5Y Revenue Exit $10.46 $18.00 $27.61 71
5Y EBITDA Exit $11.82 $20.57 $30.80 74
5Y P/E Exit $11.76 $20.46 $29.64 70
10Y Revenue Exit $10.78 $17.81 $27.28 66
10Y EBITDA Exit $12.00 $19.57 $29.69 67
10Y P/E Exit $11.96 $19.49 $28.81 63
Earnings-Based
Graham-Dodd $6.41 $21.32 $28.53 64
Lynch FV $4.83 $6.89 $8.96 61
PEG = 1.0 $4.83 $6.89 $8.96 57
EPV $7.83 $9.49 $10.92 74
Dividend Discount
Gordon GGM $0.5300 $1.05 $1.60 66
DDM Multi-Stage $0.5300 $0.8900 $1.11 67
Multiples
P/E Multiple $15.56 $20.75 $25.93 63
P/S Multiple $12.02 $16.03 $20.04 58
EV/EBIT $14.72 $20.52 $26.32 66
EV/EBITDA $13.00 $18.22 $23.44 67
EV/Revenue $9.74 $15.06 $20.38 53
Growth DCF
Growth DCF $12.89 $20.33 $30.69 78
Rev-Margin DCF $10.46 $18.05 $26.94 72
Economic Profit
ROIC Compounder $8.01 $9.90 $11.65 72
Growth Earnings
Growth-Adj P/E $13.10 $18.71 $24.33 67

Open the full fair value analysis →

Notify me when BTMD reaches fair value

Put BTMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 76/100

Of which business quality 75 · Market factors (momentum, volatility) 2

Profitability 90
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 68
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 7
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−27.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.2%
Dividend (yield on the price)4.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 20%
2025 sits 567% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Watch BTMD, get fair value alerts →

Compare biote Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 251 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside −10.9% · Below median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 13.7% · Top 25%
Net margin (TTM) 3.2% · Below median
Operating margin (TTM) 5.3% · Below median
Growth and dividend
Revenue growth −9.5% · Bottom 25%
Dividend yield (TTM) 4.4% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 8.2× · Cheapest 25%
P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.21× · Cheapest 25%
P/FCF 1.3× · Cheapest 25%
EV/EBITDA 4.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 33
FUTURE (revenue growth)0 · sector 26
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)89 · sector 40

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $426.69 $597.97 +40%
Fresenius SE FRE €43.64 €34.49 −21%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $258.62 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.25 $45.37 +104%
DaVita Inc DVA $178.69 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

biote Corp · Fair Value
$1.03 −8%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "biote Corp Fair Value". https://www.fairvalue-calculator.com/stock/BTMD

Frequently asked questions

Is biote Corp (BTMD) overvalued or undervalued?
As of Oct 5, 2026, our model estimates a fair value of $1.03 versus a price of $1.12, about −8% upside (fairly valued).
What is the fair value of BTMD?
Our model-based fair value for biote Corp is $1.03 (as of Oct 5, 2026), built from audited fundamentals. The current price: $1.12.
What is the quality score of BTMD?
biote Corp has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for biote Corp (BTMD)?
Our model-based price target is the fair value of $1.03 (as of Oct 5, 2026) from 23 valuation models. Cautious scenario $0.6333, optimistic scenario $1.39. It is a calculation from audited fundamentals, not an analyst target.
What is the biote Corp stock forecast for 2026?
Our models put fair value at $1.03, about −8% upside versus a price of $1.12 (fairly valued). Cautious scenario $0.6333, optimistic scenario $1.39. The calculation is refreshed regularly with new filings.
What is the revenue of biote Corp (BTMD)?
biote Corp reported trailing-twelve-month revenue of about $184M (latest available figure, as of Oct 5, 2026).
Does biote Corp pay a dividend?
biote Corp currently shows a dividend yield of about 4.43% relative to its recent price (as of Oct 5, 2026).
What is the intrinsic value of biote Corp (BTMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For biote Corp it is $1.03 per share (as of Oct 5, 2026), against a price of $1.12. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is biote Corp stock overvalued or undervalued in 2026?
As of Oct 5, 2026, BTMD trades above its calculated fair value: price $1.12, fair value $1.03, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BTMD?
No. The price is what the market pays today ($1.12); the fair value is what the company's own numbers justify ($1.03). For biote Corp the two are $0.0950 per share apart. That gap is exactly why we show both numbers side by side.
How much is biote Corp worth?
The market values biote Corp at about $39.0M (market capitalisation, as of Oct 5, 2026). Per share that is $1.12; our models calculate a fair value of $1.03 per share.
What do the bullish and bearish scenarios say about BTMD?
Our models span a range for biote Corp: cautious scenario $0.6333, base $1.03, optimistic $1.39 per share (as of Oct 5, 2026, price $1.12). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BTMD?
biote Corp trades at a price-to-earnings ratio of 8.2 (as of Oct 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.03 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 2.0 (reported for FY2025: 1.3). Other multiples: P/S 0.2, EV/EBITDA 4.5.
How solid is the balance sheet of biote Corp (BTMD)?
Balance-sheet figures for biote Corp (as of Oct 5, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is BTMD from its 52-week high?
biote Corp trades at $1.12, about 65% below its 52-week high of $3.19 and at the low of $1.12 (as of Oct 5, 2026). Distance from the high says nothing about value: that is what the fair value of $1.03 is for.
Which stocks are comparable to biote Corp?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is biote Corp stock attractive at the current price?
The data as of Oct 5, 2026: price $1.12, calculated fair value $1.03 (−8%), Quality Score 76/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BTMD calculated?
We run biote Corp through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. biote Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of biote Corp (BTMD)?
The closing price on Oct 5, 2026 was $1.12. Our model-based fair value is $1.03, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with biote Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.6333 to $1.39) leaves room in how you read the outcome.

Key figures of biote Corp

How large is the market capitalisation of biote Corp (BTMD)?
The market capitalisation of biote Corp is $39.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of biote Corp (BTMD)?
The price-to-sales ratio of biote Corp is 1.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of biote Corp (BTMD)?
Earnings per share at biote Corp are $0.1400 (price ÷ EPS = P/E 8.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of biote Corp (BTMD)?
The dividend yield of biote Corp is 4.4% (payout 35.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of biote Corp (BTMD)?
The net margin of biote Corp is 14.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of biote Corp (BTMD)?
On an EBIT basis the return on assets of biote Corp is 18.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of biote Corp (BTMD)?
The operating margin of biote Corp is 5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at biote Corp (BTMD)?
Revenue at biote Corp is growing −9.5% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at biote Corp (BTMD)?
Earnings per share at biote Corp are growing −83.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does biote Corp (BTMD) generate?
The free cash flow of biote Corp is $30.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does biote Corp (BTMD) carry?
The net debt of biote Corp is $85.8M (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch biote Corp in the live analysis

One click puts biote Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.